Pharmaceutical News and Articles

Excerpt of SEC Filnig by Amgen, Inc.

THOUSAND OAKS, Calif., March 1, 2007 - Below is an excerpt from an SEC filing by Amgen, Inc. that says the company received an informal inquiry from the SEC's regarding a study of the drug Aranesp. The full filing is attached.



"On February 19, 2007, Amgen received an informal inquiry from the SEC’s Atlanta District Office regarding the Danish Head and Neck Cancer (DAHANCA) 10 study (the “Study”). The SEC’s Atlanta District Office has requested that Amgen voluntarily provide certain information and documentation related to the Study. We intend to fully cooperate with the request."

Latest Clinical Trial Results...

Clinical Trial Results Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

MedNotes
Advertisement

(web2)